MLTO Medirect Latino Inc (CE)

MEDirect Latino, Inc., (OTCPK: MLTO): -- We continue to show significant revenue increases on a monthly basis with a customer stick ratio of 99%. As we enter a new year, we expect our gross revenues to increase dramatically in conjunction with our 2006 national television advertising campaign and our improved marketing efforts in Puerto Rico. MEDirect Latino, Inc., (OTCPK: MLTO) is pleased to announce a well-respected firm TSC, has upgraded their equity rating on MLTO. This strong upgrade comes at a time when the company is reporting month over month record revenue growth with plans for doubling its employee base within the quarter. TSC is noted for their work with, account executives, analysts, portfolio managers, institutions, venture capital investors, individual investors and the media. To view the entire independent research report, please click on the attached URL: http://www.otclive.com or visit: http://www.medirectlatino.org. Ms. Debra Towsley, President of MEDirect Latino, Inc. states, "We are honored to have a quality independent research firm review our overall operations, progress and to provide the resulting upgrade in our stock. This provides further confirmation to our shareholders that our company is headed in the right direction". Ms. Towsley further stated, "2005 has been a record year for our company. We continue to show significant revenue increases on a monthly basis with a customer stick ratio of 99%. As we enter a new year, we expect our gross revenues to increase dramatically in conjunction with our 2006 national television advertising campaign and our improved marketing efforts in Puerto Rico. We conservatively estimate the current Hispanic market for our Medicare reimbursed medical products to be $748MM in the continental United States." ABOUT MEDIRECT LATINO: MEDirect Latino (OTCPK:MLTO) is a rapidly growing, uniquely positioned provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico. MEDirect is the only company positioned to serve the U.S. Hispanic healthcare market as a direct-to-consumer Medicare provider on an authentically national level. The Company's current focus is the distribution of products for the treatment of Type II diabetes specifically because of its disproportionate impact and increasing diagnosis rate within the US Hispanic population, noting an incidence of 120% higher than among non-Hispanic whites. Safe Harbor Disclosure: This press release includes ``forward-looking statements'' within the meaning of the federal securities laws, commonly identified by such terms as ``believes,'' ``looking ahead,'' ``anticipates,'' ``estimates'' and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.